Genetic Technologies Stock Performance
| GENE Stock | USD 0.77 0.00 0.00% |
The company retains a Market Volatility (i.e., Beta) of 0.0371, which attests to not very significant fluctuations relative to the market. As returns on the market increase, Genetic Technologies' returns are expected to increase less than the market. However, during the bear market, the loss of holding Genetic Technologies is expected to be smaller as well. At this point, Genetic Technologies has a negative expected return of -0.23%. Please make sure to check out Genetic Technologies' total risk alpha, as well as the relationship between the skewness and day median price , to decide if Genetic Technologies performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days Genetic Technologies has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of weak performance in the last few months, the Stock's basic indicators remain rather sound which may send shares a bit higher in December 2024. The latest tumult may also be a sign of longer-term up-swing for the firm shareholders. ...more
Last Split Factor 1:5 | Dividend Date 2019-08-15 | Last Split Date 2023-12-14 |
1 | Acquisition by Riedel Norbert G of 271 shares of Genetic Technologies at 1.98 subject to Rule 16b-3 | 09/03/2024 |
2 | Join Genetic Technologys Exclusive Live Investor Webinar and QA Session on October 2 | 09/23/2024 |
3 | Insider Trading | 10/01/2024 |
4 | Pet DNA Testing Market Report 2024 Industry Analysis and Forecast with Share Strategy Insights of Leading Players - Zoetis , Mars Petcare , Orivet Genetic Pet C... | 10/15/2024 |
5 | Acquisition by Hennessey Robert J of 14000 shares of Genetic Technologies at 1.625 subject to Rule 16b-3 | 10/30/2024 |
6 | Disposition of tradable shares by Loucks Vernon R Jr of Genetic Technologies subject to Rule 16b-3 | 11/01/2024 |
7 | Disposition of 10000 shares by Hennessey Robert J of Genetic Technologies at 5.5003 subject to Rule 16b-3 | 11/08/2024 |
8 | Genetic Technologies appoints voluntary administrators | 11/20/2024 |
| Begin Period Cash Flow | 7.9 M |
Genetic |
Genetic Technologies Relative Risk vs. Return Landscape
If you would invest 90.00 in Genetic Technologies on August 28, 2024 and sell it today you would lose (13.00) from holding Genetic Technologies or give up 14.44% of portfolio value over 90 days. Genetic Technologies is currently does not generate positive expected returns and assumes 1.6829% risk (volatility on return distribution) over the 90 days horizon. In different words, 14% of stocks are less volatile than Genetic, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Genetic Technologies Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Genetic Technologies' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Genetic Technologies, and traders can use it to determine the average amount a Genetic Technologies' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.1386
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | GENE |
Estimated Market Risk
| 1.68 actual daily | 14 86% of assets are more volatile |
Expected Return
| -0.23 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.14 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Genetic Technologies is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Genetic Technologies by adding Genetic Technologies to a well-diversified portfolio.
Genetic Technologies Fundamentals Growth
Genetic Stock prices reflect investors' perceptions of the future prospects and financial health of Genetic Technologies, and Genetic Technologies fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Genetic Stock performance.
| Return On Equity | -1.85 | ||||
| Return On Asset | -0.63 | ||||
| Profit Margin | (1.24) % | ||||
| Operating Margin | (1.13) % | ||||
| Current Valuation | 3.6 M | ||||
| Shares Outstanding | 4.85 M | ||||
| Price To Earning | (1.87) X | ||||
| Price To Book | 3.11 X | ||||
| Price To Sales | 0.38 X | ||||
| Revenue | 7.66 M | ||||
| Gross Profit | 6.01 M | ||||
| EBITDA | (11.43 M) | ||||
| Net Income | (12.02 M) | ||||
| Cash And Equivalents | 11.74 M | ||||
| Cash Per Share | 0.76 X | ||||
| Total Debt | 875.19 K | ||||
| Debt To Equity | 0.04 % | ||||
| Current Ratio | 3.86 X | ||||
| Book Value Per Share | 0.01 X | ||||
| Cash Flow From Operations | (9.68 M) | ||||
| Earnings Per Share | (0.02) X | ||||
| Market Capitalization | 3.71 M | ||||
| Total Asset | 6.19 M | ||||
| Retained Earnings | (166.38 M) | ||||
| Working Capital | (500.09 K) | ||||
| Current Asset | 9.03 M | ||||
| Current Liabilities | 992 K | ||||
About Genetic Technologies Performance
By analyzing Genetic Technologies' fundamental ratios, stakeholders can gain valuable insights into Genetic Technologies' financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Genetic Technologies has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Genetic Technologies has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 20.04 | 19.04 | |
| Return On Tangible Assets | (2.97) | (2.82) | |
| Return On Capital Employed | (3.28) | (3.12) | |
| Return On Assets | (1.94) | (1.85) | |
| Return On Equity | (6.57) | (6.24) |
Things to note about Genetic Technologies performance evaluation
Checking the ongoing alerts about Genetic Technologies for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Genetic Technologies help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Genetic Technologies generated a negative expected return over the last 90 days | |
| Genetic Technologies has some characteristics of a very speculative penny stock | |
| Genetic Technologies has a very high chance of going through financial distress in the upcoming years | |
| The company reported the previous year's revenue of 7.66 M. Net Loss for the year was (12.02 M) with profit before overhead, payroll, taxes, and interest of 6.01 M. | |
| Genetic Technologies currently holds about 11.74 M in cash with (9.68 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.76. | |
| Latest headline from investing.com: Genetic Technologies appoints voluntary administrators |
- Analyzing Genetic Technologies' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Genetic Technologies' stock is overvalued or undervalued compared to its peers.
- Examining Genetic Technologies' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Genetic Technologies' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Genetic Technologies' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Genetic Technologies' stock. These opinions can provide insight into Genetic Technologies' potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Genetic Stock analysis
When running Genetic Technologies' price analysis, check to measure Genetic Technologies' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Genetic Technologies is operating at the current time. Most of Genetic Technologies' value examination focuses on studying past and present price action to predict the probability of Genetic Technologies' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Genetic Technologies' price. Additionally, you may evaluate how the addition of Genetic Technologies to your portfolios can decrease your overall portfolio volatility.
| Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets | |
| Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
| Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
| Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm | |
| Analyst Advice Analyst recommendations and target price estimates broken down by several categories |